Increasing potency and price of cannabis in Europe, 2006–16

Addiction

Volumn 114, Issue 6, 2019, Pages 1015-1023

  Freeman, Tom P ^a,b   Groshkova, Teodora ^c   Cunningham, Andrew ^c   Sedefov, Roumen ^c   Griffiths, Paul ^c   Lynskey, Michael T ^b  

^a University of Bath   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

Author keywords

Cannabis; drug markets; herbal; potency; price; resin; THC

Indexed keywords

CANNABIS; DRONABINOL; PLANT RESIN;

CHEMISTRY; COMMERCIAL PHENOMENA; CROSS-SECTIONAL STUDY; ECONOMICS; EUROPE; EUROPEAN UNION; HUMAN; NORWAY; TURKEY (BIRD);

CANNABIS; COMMERCE; CROSS-SECTIONAL STUDIES; DRONABINOL; EUROPE; EUROPEAN UNION; HUMANS; NORWAY; RESINS, PLANT; TURKEY;

EID: 85060128286     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.14525     Document Type: Article

References (50)

1. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2018. Sales no. E18XI9. Herndon, VA, USA: United Nations Publications; 2018.
2. Di Forti M., Marconi A., Carra E., Fraietta S., Trotta A., Bonomo M. et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case–control study. Lancet Psychiatry 2015; 2: 233–238.
3. Freeman T., Winstock A. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med 2015; 45: 3181–3189.
4. Chan G. C., Hall W., Freeman T. P., Ferris J., Kelly A. B., Winstock A. User characteristics and effect profile of Butane Hash Oil: an extremely high-potency cannabis concentrate. Drug Alcohol Depend 2017; 178: 32–38.
5. Meier M. H. Associations between butane hash oil use and cannabis-related problems. Drug Alcohol Depend 2017; 179: 25–31.
6. Freeman T. P., van der Pol P., Kuijpers W., Wisselink J., Das R. K., Rigter S. et al. Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands. Psychol Med 2018; 48: 2346–2352.
7. van der Pol P., Liebregts N., de Graaf R., Korf D. J., van den Brink W., van Laar M. Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug Alcohol Depend 2013; 133: 352–359.
8. Freeman T. P., Morgan C. J., Hindocha C., Schafer G., Das R. K., Curran H. V. Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction 2014; 109: 1686–1694.
9. van der Pol P., Liebregts N., Brunt T., Amsterdam J., Graaf R., Korf D. J. et al. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 2014; 109: 1101–1109.
10. Curran H. V., Freeman T. P., Mokrysz C., Lewis D. A., Morgan C. J., Parsons L. H. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 2016; 17: 293–306.
11. Freeman T., Swift W. Cannabis potency: the need for global monitoring. Addiction 2016; 111: 376–377.
12. van Laar M., van der Pol P., Niesink R. Limitations to the Dutch cannabis toleration policy: assumptions underlying the reclassification of cannabis above 15% THC. Int J Drug Policy 2016; 34: 58–64.
13. Wilson J., Freeman T. P., Mackie C. J. Effects of increasing cannabis potency on adolescent health. Lancet Child Adolesc Health 2018; https://doi.org/10.1016/S2352-4642(18)30342-0.
14. European Monitoring Centre for Drugs and Drug Addiction and Europol (EMCDDA). EU Drug Markets Report: In-Depth Analysis. Luxembourg: Publications Office of the European Union; 2016.
15. Englund A., Freeman T. P., Murray R. M., McGuire P. Can we make cannabis safer? Lancet Psychiatry 2017; 4: 643–648.
16. Boggs D. L., Nguyen J. D., Morgenson D., Taffe M. A., Ranganathan M. Clinical and preclinical evidence for functional interactions of cannabidiol and δ9-tetrahydrocannabinol. Neuropsychopharmacology 2018; 43: 142–154.
17. Colizzi M., Bhattacharyya S. Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Curr Addict Rep 2017; 4: 62–74.
18. Potter D. J., Clark P., Brown M. B. Potency of Δ9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 2008; 53: 90–94.
19. de Meijer E. P., Bagatta M., Carboni A., Crucitti P., Moliterni V. C., Ranalli P. et al. The inheritance of chemical phenotype in Cannabis sativa L. Genetics 2003; 163: 335–346.
20. Raber J. C., Elzinga S., Kaplan C. Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J Toxicol Sci 2015; 40: 797–803.
21. Stambouli H., El Bouri A., Bouayoun T. Évolution de la teneur en Δ9-THC dans les saisies de résines de cannabis au Maroc de 2005 à 2014 [Trend of δ9-THC content of cannabis resin seized in Morocco from 2005 to 2014]. Toxicol Anal Clin 2016; 28: 146–152.
22. Chouvy P.-A., Afsahi K. Hashish revival in Morocco. Int J Drug Policy 2014; 25: 416–423.
23. Dujourdy L., Besacier F. A study of cannabis potency in France over a 25 years period (1992–2016). Forensic Sci Int 2017; 272: 72–80.
24. Potter D. J., Hammond K., Tuffnell S., Walker C., Di Forti M. Potency of Δ9-tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: implications for public health and pharmacology. Drug Test Anal 2018; 10: 628–635.
25. Zamengo L., Frison G., Bettin C., Sciarrone R. Variability of cannabis potency in the Venice area (Italy): a survey over the period 2010–2012. Drug Test Anal 2014; 6: 46–51.
26. Zamengo L., Frison G., Bettin C., Sciarrone R. Cannabis potency in the Venice area (Italy): update 2013. Drug Test Anal 2015; 7: 255–258.
27. Niesink R. J., Rigter S., Koeter M. W., Brunt T. M. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–15. Addiction 2015; 110: 1941–1950.
28. Pijlman F., Rigter S., Hoek J., Goldschmidt H., Niesink R. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol 2005; 10: 171–180.
29. Cascini F., Aiello C., Di Tanna G. Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 2012; 5: 32–40.
30. van der Pol P., Liebregts N., Graaf R., Korf D. J., Brink W., van Laar M. Validation of self-reported cannabis dose and potency: an ecological study. Addiction 2013; 108: 1801–1808.
31. Smart R., Caulkins J. P., Kilmer B., Davenport S., Midgette G. Variation in cannabis potency and prices in a newly-legal market: evidence from 30 million cannabis sales in Washington State. Addiction 2017; 112: 2167–2177.
32. Caulkins J. P., Bao Y., Davenport S., Fahli I., Guo Y., Kinnard K. et al. Big data on a big new market: insights from Washington State's legal cannabis market. Int J Drug Policy 2018; 57: 86–94.
33. Goudie A. J., Sumnall H. R., Field M., Clayton H., Cole J. C. The effects of price and perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases. Drug Alcohol Depend 2007; 89: 107–115.
34. Kelly T. H., Foltin R. W., Emurian C. S., Fischman M. W. Are choice and self-administration of marijuana related to Δ–9-THC content? Exp Clin Psychopharmacol 1997; 5: 74–82.
35. Bedi G., Lindquist M. A., Haney M. An fMRI-based neural signature of decisions to smoke cannabis. Neuropsychopharmacology 2015; 40: 2657–2665.
36. Von Elm E., Altman D. G., Egger M., Pocock S. J., Gøtzsche P. C., Vandenbroucke J. P. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–1457.
37. West R., Marsden J., Humphreys K., Darke S. A revised checklist for writing up research reports. Addiction 2018; 113: 1567–1570.
38. Singleton N., Cunningham A., Groshkova T., Royuela L., Sedefov R. Drug supply indicators: pitfalls and possibilities for improvements to assist comparative analysis. Int J Drug Policy 2018; 56: 131–136.
39. EMCDDA. Developing drug supply monitoring in Europe: current concepts. Luxembourg: EMCDDA Papers, Publications Office of the European Union; 2017.
40. Raftery A. E. Bayesian model selection in social research. Sociol Methodol 1995; 25: 111–163.
41. ElSohly M. A., Mehmedic Z., Foster S., Gon C., Chandra S., Church J. C. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry 2016; 79: 613–619.
42. Potter D. J., Hammond K., Tuffnell S., Walker C., Di Forti M. Potency of Δ9–tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology. Drug Test Anal 2018; 10: 628–635.
43. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Treatment of Cannabis-Related Disorders in Europe. Luxembourg: Publications Office of the European Union; 2015.
44. Morgan C. J., Freeman T. P., Hindocha C., Schafer G., Gardner C., Curran H. V. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 2018; 8: 181.
45. Morgan C. J., Schafer G., Freeman T. P., Curran H. V. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 2010; 197: 285–290.
46. Englund A., Morrison P. D., Nottage J., Hague D., Kane F., Bonaccorso S. et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013; 27: 19–27.
47. Bhattacharyya S., Morrison P. D., Fusar-Poli P., Martin-Santos R., Borgwardt S., Winton-Brown T. et al. Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35: 764–774.
48. Rømer Thompsen K., Lindholst C., Thylstrup B., Kvamme S., Englund A., Freeman T. P. et al. Changes in the composition of cannabis from 2000-2017 in Denmark: analysis of confiscated samples of cannabis resin. Exp Clin Psychopharmacol; in press.
49. Rømer Thomsen K. R., Callesen M. B., Ewing S. W. F. Recommendation to reconsider examining cannabis subtypes together due to opposing effects on brain, cognition and behavior. Neurosci Biobehav Rev 2017; 80: 156–158.
50. Raudenbush S. W. Random effects models. In: Cooper H., Hedges L. V., editors. The Handbook of Research Synthesis. New York: Russell Sage Foundation, pp. 301–321.